semaglutide ghrelin Six-month changes in and glucagon-like peptide-1 with weight loss are unrelated to long-term weight regain in obese older adults Hormonal Gut–Brain Signaling for the

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort are dose-dependent and usually improve with slow titration

Tirzepatide is a dual GIP/GLP-1 agonist that has shown even greater weight loss in clinical trials

Histologic evidence from massive weight loss demonstrates increased elastic fiber density compared to morbidly obese skin, but altered collagen architecture and decreased dermal thickness are common, which can translate to visible laxity even if elastic fibers are on the rise

Related Stories Poor sleep alters brain communication networks differently across adult lifespan Study reveals high prevalence of post-pandemic fatigue and sleep disturbances Study maps how exercise, sleep, diet, and mood connect in daily life Multinomial logistic regression estimated associations between pre-workout use and sleep categories, adjusting for covariates

Reality The medication reduces baseline hunger and alters reward valuation, but it does not eliminate the need for mindful choices